Compare NFLX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NFLX | MRK |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.4B | 317.8B |
| IPO Year | 2000 | 1994 |
| Metric | NFLX | MRK |
|---|---|---|
| Price | $70.22 | $131.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 34 | 17 |
| Target Price | $119.23 | ★ $125.59 |
| AVG Volume (30 Days) | ★ 39.6M | 6.5M |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 2.03 | N/A |
| Revenue | $45,183,036,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $15.99 | $3.61 |
| Revenue Next Year | $11.74 | $5.41 |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | ★ 15.85 | 1.31 |
| 52 Week Low | $65.08 | $76.66 |
| 52 Week High | $1,267.10 | $131.74 |
| Indicator | NFLX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 62.78 |
| Support Level | $65.08 | $112.68 |
| Resistance Level | $78.44 | N/A |
| Average True Range (ATR) | 2.15 | 3.05 |
| MACD | -0.04 | 0.30 |
| Stochastic Oscillator | 40.69 | 98.53 |
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).